Skip to main content

Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?

Publication ,  Journal Article
Prasanna, PG; Woloschak, GE; DiCarlo, AL; Buchsbaum, JC; Schaue, D; Chakravarti, A; Cucinotta, FA; Formenti, SC; Guha, C; Hu, DJ; Khan, MK ...
Published in: Radiat Res
November 10, 2020

The limited impact of treatments for COVID-19 has stimulated several phase 1 clinical trials of whole-lung low-dose radiation therapy (LDRT; 0.3-1.5 Gy) that are now progressing to phase 2 randomized trials worldwide. This novel but unconventional use of radiation to treat COVID-19 prompted the National Cancer Institute, National Council on Radiation Protection and Measurements and National Institute of Allergy and Infectious Diseases to convene a workshop involving a diverse group of experts in radiation oncology, radiobiology, virology, immunology, radiation protection and public health policy. The workshop was held to discuss the mechanistic underpinnings, rationale, and preclinical and emerging clinical studies, and to develop a general framework for use in clinical studies. Without refuting or endorsing LDRT as a treatment for COVID-19, the purpose of the workshop and this review is to provide guidance to clinicians and researchers who plan to conduct preclinical and clinical studies, given the limited available evidence on its safety and efficacy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Radiat Res

DOI

EISSN

1938-5404

Publication Date

November 10, 2020

Volume

194

Issue

5

Start / End Page

452 / 464

Location

United States

Related Subject Headings

  • Translational Research, Biomedical
  • Risk
  • Radiotherapy Dosage
  • Radiation Dosage
  • Pneumonia, Viral
  • Pandemics
  • Oncology & Carcinogenesis
  • Humans
  • Coronavirus Infections
  • Clinical Trials as Topic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Prasanna, P. G., Woloschak, G. E., DiCarlo, A. L., Buchsbaum, J. C., Schaue, D., Chakravarti, A., … Held, K. D. (2020). Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks? Radiat Res, 194(5), 452–464. https://doi.org/10.1667/RADE-20-00211.1
Prasanna, Pataje G., Gayle E. Woloschak, Andrea L. DiCarlo, Jeffrey C. Buchsbaum, Dörthe Schaue, Arnab Chakravarti, Francis A. Cucinotta, et al. “Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?Radiat Res 194, no. 5 (November 10, 2020): 452–64. https://doi.org/10.1667/RADE-20-00211.1.
Prasanna PG, Woloschak GE, DiCarlo AL, Buchsbaum JC, Schaue D, Chakravarti A, et al. Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks? Radiat Res. 2020 Nov 10;194(5):452–64.
Prasanna, Pataje G., et al. “Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?Radiat Res, vol. 194, no. 5, Nov. 2020, pp. 452–64. Pubmed, doi:10.1667/RADE-20-00211.1.
Prasanna PG, Woloschak GE, DiCarlo AL, Buchsbaum JC, Schaue D, Chakravarti A, Cucinotta FA, Formenti SC, Guha C, Hu DJ, Khan MK, Kirsch DG, Krishnan S, Leitner WW, Marples B, McBride W, Mehta MP, Rafii S, Sharon E, Sullivan JM, Weichselbaum RR, Ahmed MM, Vikram B, Coleman CN, Held KD. Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks? Radiat Res. 2020 Nov 10;194(5):452–464.

Published In

Radiat Res

DOI

EISSN

1938-5404

Publication Date

November 10, 2020

Volume

194

Issue

5

Start / End Page

452 / 464

Location

United States

Related Subject Headings

  • Translational Research, Biomedical
  • Risk
  • Radiotherapy Dosage
  • Radiation Dosage
  • Pneumonia, Viral
  • Pandemics
  • Oncology & Carcinogenesis
  • Humans
  • Coronavirus Infections
  • Clinical Trials as Topic